Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 866.43M P/E - EPS this Y 13.30% Ern Qtrly Grth -
Income -65.14M Forward P/E -36.73 EPS next Y 73.10% 50D Avg Chg 13.00%
Sales 210M PEG -0.88 EPS past 5Y - 200D Avg Chg 27.00%
Dividend N/A Price/Book 7.15 EPS next 5Y 30.00% 52W High Chg -21.00%
Recommedations 1.50 Quick Ratio 3.58 Shares Outstanding 235.43M 52W Low Chg 453.00%
Insider Own 1.62% ROA -13.27% Shares Float 229.90M Beta 0.89
Inst Own 61.83% ROE -48.23% Shares Shorted/Prior 25.93M/25.98M Price 4.04
Gross Margin 66.27% Profit Margin -31.02% Avg. Volume 5,148,887 Target Price 11.65
Oper. Margin -18.62% Earnings Date Oct 29 Volume 10,175,200 Change 5.21%
About Ardelyx, Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc. News
10/09/24 Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges
10/09/24 Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years
10/09/24 Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
10/07/24 Wall Street Analysts Think Ardelyx (ARDX) Could Surge 65.4%: Read This Before Placing a Bet
09/12/24 Top High Growth Tech Stocks to Watch in September 2024
09/05/24 Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
08/30/24 With 62% ownership, Ardelyx, Inc. (NASDAQ:ARDX) boasts of strong institutional backing
08/08/24 Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
08/01/24 Here's What Key Metrics Tell Us About Ardelyx (ARDX) Q2 Earnings
08/01/24 Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
08/01/24 Ardelyx: Q2 Earnings Snapshot
08/01/24 Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
07/31/24 Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
07/29/24 Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
07/25/24 Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
07/18/24 Ardelyx sues CMS over revamped kidney disease drug payment bundle
07/18/24 Ardelyx, Groups File Lawsuit Over Dialysis Payment System Coverage
07/18/24 Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
07/17/24 Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
07/15/24 Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
ARDX Chatroom

User Image watsonturtle Posted - 13 minutes ago

$ARDX Just my view, but I have more faith in the judge issuing an injunction against CMS than I do in the politicians getting off their collective dumb asses and getting something done. They all seem to be distracted ... the political arena is a bizarre, world ... god damn bunch of barken farkers. WT

User Image Food4Thought Posted - 2 hours ago

$ARDX A new hire and position filled.

User Image Food4Thought Posted - 2 hours ago

$ARDX Ardelyx showing support for military and veterans. Much appreciated and I think will buy more shares.

User Image rwallstreetnow Posted - 2 hours ago

$ARDX

User Image newsfile_corp Posted - 3 hours ago

https://nfne.ws/220475 $ARDX @BGandG_Law #Banking #FinancialServices #NASDAQ #Investing

User Image watsonturtle Posted - 4 hours ago

$ARDX suppose this pin at 6 could have sum-ting to do with OPEX this coming friday ... OI of about 4400 contracts at strike price of 6. It would be great fun if the judge dropped an order on Thursday 10/17 enjoining CMS from implementing its regulation to bundle Xphozah. Briefs will be all in by 10/16 and IMO it should not be difficult to see CMS's overreach. The Judge could drop the order on Thursday, and then file her detailed decision with reasoning next week. WT

User Image Coach_B1067 Posted - 4 hours ago

$ARDX Piffed is starting to look pretty good on his prediction for closing price today.

User Image A_Train1 Posted - 4 hours ago

$ARDX this stock is a daytraders dream…probably making a killing buying and selling on the 20 cent range. Wow. Like easy money.

User Image ToadTrader Posted - 4 hours ago

$ARDX Life of a day Trader, you look ay many.... pick a short list of "MOST LIKELY" then pick a few to focus on.... and then you end up with this: (LOL) >>List of 20....10, now showing, thus far, RED for the DAY! >> The range between the biggest gain vs vs biggest loss.... 13% Gain vs a 9% drop. Some noted Low of Day to High of DAY (thus far!) >>(WULF) a nice dip to $4.22 then Run up to $4.55 (33-cents; 7.79% gain) >>(EYPT) Continuation from Friday 8.82 on open to current high $10.14 ($1.31 per share 14.89% gain! so far) >> (CAPR) a nice dip to $17.02 then Run up to $19.79 ($2.76 per share; 16.21% gain) That's the good news! LOL... I took a hit on another stock... Skinny RED DAY , simply picking the wrong one to focus on....LOL Trade the plan.... Manage for Loss and have fun!

User Image ekpemofolo Posted - 5 hours ago

Meanwhile the situation in biolandia: $KPTI holding nicely 80's. Goals are further ahead, but I wouldn't mind some breeze in the sails. $CTXR testing loyalty from retail. I suspect only those who trust their DD will remain after this bloodshed. $ARDX it is only a matter of "when" and "how much".

User Image Sven1988 Posted - 5 hours ago

$ARDX oh no it’s down 10 Cents today. Im gonna cry all day…

User Image A_Train1 Posted - 5 hours ago

$ARDX come on ARDX…let’s go!

User Image ToadTrader Posted - 5 hours ago

$ARDX Some may be noticing that I have been rather "quiet" with throwing out suggestions of price action, of late! Its not that I don't have my own "expectations", but more out of the respect for others as individuals assess their own status and stability in their Trading Plans! There is a reality, that some others here admit to when it comes to "assessing expectations of price movement.... There are times your assessment, gives you area that I see as "of interest"! But... I have yet to find a way, to "SUGGEST" the "WHEN" part of the process. That alone, becomes a bit more complex in that there are a lot of factors involved with this stock in recent weeks! For me, the Complexity of "Mondays" come in to play as I trade against several charts of a stock at the same time.... Tracking Trend via the WEEKLY.... the 24-hr, chart... and then AS A DAY TRADER, I assess with shorter time frames for daily trading possibilities! Still watching closely.... Trade safe...Trade your Plan!

User Image Bluefin1976 Posted - 5 hours ago

$ARDX 5.50 incoming

User Image TragicRain Posted - 5 hours ago

$ARDX - someone has to be selling - its down $1 per share since 10/2

User Image PIFFED Posted - 6 hours ago

$ARDX MM’s selling shares back and forth waiting on retail to get discouraged and sell? Normal pattern trying to shake the trees one more time before the big ER push. No one is selling, call values show that as well.

User Image ChandlerBing74 Posted - 6 hours ago

@Megan342 i am 100% in $ARDX

User Image KevinDL Posted - 7 hours ago

$ARDX Damn! Must be lunch time.

User Image bams1017 Posted - 7 hours ago

$ARDX Scrolling through the LBPH thread here on ST - found this from last month (Sept).. Baird analyst Joel Beatty reiterated an Outperform rating and $60.00 price target on Longboard Pharmaceuticals Inc (NASDAQ: $LBPH). The analyst commented: "Longboard's investor and analyst event focused on the phase 3 plans for bexicaserin for the treatment of Developmental and Epileptic Encephalopathies (DEEs), and was largely in line with investor expectations, in our view. The phase 3 program is expected to initiate around the end of September, with topline results around YE26. We continue to see meaningful longer-term upside for the stock, because we believe bexicaserin is likely to succeed in phase 3 and sales are likely to exceed $1B/year." okay... don't know what other stuff they have in their R&D pipeline...but here we got a medication that is not approved (P3 to begin) and $1B peak revenue. And this sells out for 2.6x peak revenue potential for a medication that still has a ways to go

User Image Greenbeanbro Posted - 8 hours ago

@newandimproveddonkeykong @jstnfstr I just want to break even on my UNCY bags at this point lol. They may eventually be something other than vaporware, but I don't see how a 14 person company commercializes any molecule. Maybe they sell out to $ARDX?

User Image ToadTrader Posted - 8 hours ago

$ARDX $6.06 Need some taters to go with that!

User Image ChandlerBing74 Posted - 9 hours ago

$ARDX I can't find the transcript of July 2nd conference call when they announced they weren't applying for TDAPA, but one thing Raab said stucked with me. ''Do not understimate us'' Even though that decision hampered my short term trading plans, Raad doesn't give a rat's a$$ about our short term goals. He's working on the long term value of the company. As he should. It's on us to adapt and stop whining for our failed trading plans

User Image newandimproveddonkeykong Posted - 9 hours ago

$ARDX Unicycive couldn't compete with a lemonade stand. Their entire business model is based on raising money off of PRs they put out every time the FDA replies to one of their emails (even if it is to tell UNCY that they have never provided enough data to prove they are running serious trials).

User Image ToadTrader Posted - 10 hours ago

$ARDX Made it Back Here! Great Day! A lot to do this week with contractors coming in to rebuild roof... friends visiting... and such. So... I'll be around, reviewing the boards and pitching a few pennies on occasion! Enjoying this coffee with cool weather setting in for a few days! Leave a message as Il get back to you! Trade Safe... Trade Smart!

User Image bernardbaruch Posted - 11 hours ago

$ARDX Very well stated. Thanks R

User Image jstnfstr Posted - 11 hours ago

$ARDX Unicycive poster presentation involving combination with tenapanor. (Company looking to lighten binder burden, and other beneficial nephrology work. [Perhaps an *eventual* competitor?] See their PR today announcing several posters. And see description of their molecule. —I’ve not yet read any of the above closely at all. ) : “Title: Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rat Lead Author: Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive Session Title: CKD-MBD: Basic and Translational Poster Board: #SA-PO243 Date/Time: Saturday, October 26, 2024 from 10:00 a.m. – 12:00 p.m. PT”

User Image Alexul Posted - 12 hours ago

$ARDX Another buyout in bio sector .

User Image KevinDL Posted - 12 hours ago

$ARDX Let’s get this pre earnings rally started! I need more entertainment to get through the day.

User Image MisplacedOkie Posted - 13 hours ago

@KingNeptune $TNXP is likely to reverse split, dilute and be shorted back down from there. I went through exactly that with Allarity and lost a lot of money. There are plenty of good companies out there. It's not worth the risk. If you like biotechs, $BCTX and $ARDX both have better risk reward ratios and short term catalysts coming up.

User Image Rubberboot Posted - 15 hours ago

$ARDX Last year, ARDX announced the Q3 earnings date on Oct 18th and reported Oct 31st. Would be nice to have the same, or slightly earlier, schedule this year. I expect the company to continue on their conservative "not getting over our skis" (to quote Raab's favorite expression) line in terms of providing forward looking information. But I'd welcome some level of detail on the expectations as regards the different possible scenarios of the bundling issue first and foremost, as well as international expansion plans. Guidance for the first full year of X sales would be a bonus but I'm not counting on getting it. Anyway, this would be a good time to create some confidence among investors.

Analyst Ratings
HC Wainwright & Co. Buy Aug 5, 24
Citigroup Buy Aug 2, 24
Wedbush Outperform Aug 2, 24
HC Wainwright & Co. Buy Jul 18, 24
Wedbush Outperform Jul 18, 24
Citigroup Buy Jul 3, 24
Cantor Fitzgerald Overweight Jun 20, 24
Piper Sandler Overweight May 24, 24
Wedbush Outperform May 24, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rosenbaum David P. Chief Development Of.. Chief Development Officer Jan 08 Sell 6.64 30,000 199,200 286,596 01/10/24
Renz Justin A Chief Financial Offi.. Chief Financial Officer Dec 26 Sell 6.36 225,000 1,431,000 182,426 12/28/23
Renz Justin A Chief Financial Offi.. Chief Financial Officer Dec 26 Option 0.99 75,000 74,250 407,426 12/28/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Dec 18 Sell 6.07 5,675 34,447 316,596 12/20/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Dec 14 Sell 5.55 7,000 38,850 322,271 12/15/23
GRAMMER ELIZABETH A See Remarks See Remarks Dec 11 Sell 5.0785 50,000 253,925 275,675 12/13/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Dec 08 Sell 5.2738 20,000 105,476 329,271 12/08/23
Williams Laura A Chief Medical Office.. Chief Medical Officer Nov 20 Sell 4.3622 2,581 11,259 266,191 11/22/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Nov 20 Sell 4.36 3,767 16,424 113,293 11/22/23
Rodriguez Susan Chief Commercial Off.. Chief Commercial Officer Nov 20 Sell 4.3622 4,714 20,563 346,973 11/22/23
Renz Justin A Chief Financial Offi.. Chief Financial Officer Nov 20 Sell 4.3622 2,873 12,533 332,426 11/22/23
RAAB MICHAEL President & CEO President & CEO Nov 20 Sell 4.3622 11,368 49,589 867,868 11/22/23
GRAMMER ELIZABETH A See Remarks See Remarks Nov 20 Sell 4.3622 2,384 10,399 325,675 11/22/23
Felsch Robert Ora See Remarks See Remarks Nov 20 Sell 4.3622 1,044 4,554 117,066 11/22/23
Blanks Robert See Remarks See Remarks Nov 20 Sell 4.3622 2,835 12,367 260,453 11/22/23
Williams Laura A Chief Medical Office.. Chief Medical Officer Nov 15 Sell 3.9999 25,000 99,998 266,839 11/17/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Oct 10 Sell 4 1,644 6,576 365,378 10/12/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Sep 08 Sell 4.55 2,897 13,181 367,022 09/12/23
Williams Laura A Chief Medical Office.. Chief Medical Officer Jun 27 Sell 3.3453 25,000 83,632 294,430 06/29/23
Blanks Robert See Remarks See Remarks Jun 23 Sell 3.63 33,333 120,999 266,134 06/27/23
Blanks Robert See Remarks See Remarks Jun 23 Option 3.42 33,333 113,999 299,467 06/27/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Mar 29 Sell 4.6293 3,000 13,888 113,096 03/31/23
Felsch Robert Ora See Remarks See Remarks Aug 31 Buy .6188 3,000 1,856 91,418 09/01/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Aug 31 Buy 0.62 3,000 1,860 92,369 09/01/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Aug 31 Sell 0.92 3,000 2,760 89,369 09/01/22
Renz Justin A Chief Financial Offi.. Chief Financial Officer Aug 31 Buy 0.6188 3,000 1,856 263,549 09/01/22
Williams Laura A Chief Medical Office.. Chief Medical Officer Aug 31 Buy 0.6188 3,000 1,856 245,441 09/01/22
RAAB MICHAEL President & CEO President & CEO Aug 31 Buy 0.6188 3,000 1,856 665,680 09/01/22
GRAMMER ELIZABETH A See Remarks See Remarks Aug 31 Buy 0.6188 3,000 1,856 256,110 09/01/22
Rodriguez Susan Chief Commercial Off.. Chief Commercial Officer Aug 22 Sell 0.98 3,420 3,352 286,173 08/24/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Aug 22 Sell 0.98 1,955 1,916 89,369 08/24/22
Blanks Robert See Remarks See Remarks Aug 22 Sell 0.98 1,458 1,429 317,669 08/24/22
RAAB MICHAEL President & CEO President & CEO Aug 22 Sell 0.98 6,146 6,023 662,680 08/24/22
GRAMMER ELIZABETH A See Remarks See Remarks Aug 22 Sell 0.98 1,236 1,211 253,110 08/24/22
Williams Laura A Chief Medical Office.. Chief Medical Officer Aug 22 Sell 0.98 1,276 1,250 242,441 08/24/22
Renz Justin A Chief Financial Offi.. Chief Financial Officer Aug 22 Sell 0.98 1,498 1,468 260,549 08/24/22
Renz Justin A Chief Financial Offi.. Chief Financial Officer Jun 06 Sell 0.64 73,312 46,920 262,047 06/08/22
Rodriguez Susan Chief Commercial Off.. Chief Commercial Officer Jun 06 Sell 0.64 43,920 28,109 289,593 06/08/22
Blanks Robert See Remarks See Remarks Jun 06 Sell 0.64 73,312 46,920 324,315 06/08/22
GRAMMER ELIZABETH A See Remarks See Remarks Jun 06 Sell 0.64 60,821 38,925 254,346 06/08/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Jun 06 Sell 0.64 61,640 39,450 89,866 06/08/22
RAAB MICHAEL President & CEO President & CEO Jun 06 Sell 0.64 103,624 66,319 668,826 06/08/22
Blanks Robert See Remarks See Remarks Feb 22 Sell 0.67 1,752 1,174 399,116 02/25/22
SANDELL SCOTT D 10% Owner 10% Owner Dec 09 Sell 1.32 2,881,570 3,803,672 2,258,850 12/27/21
BASKETT FOREST 10% Owner 10% Owner Dec 09 Sell 1.32 2,881,570 3,803,672 2,258,850 12/27/21
GRAMMER ELIZABETH A See Remarks See Remarks Dec 15 Option 2.32 42,000 97,440 113,527 12/15/20
GRAMMER ELIZABETH A See Remarks See Remarks Dec 15 Sell 7.3 42,000 306,600 72,527 12/15/20